東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

An open-label, randomized, prospecti...

Al-Abdouli, Khuloud Asad.

FindBook

Google Book

Amazon

博客來

An open-label, randomized, prospective study to evaluate the effectiveness and safety of continuous long-term versus intermittent etanercept in the treatment of psoriasis.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	An open-label, randomized, prospective study to evaluate the effectiveness and safety of continuous long-term versus intermittent etanercept in the treatment of psoriasis./
作者:	Al-Abdouli, Khuloud Asad.
面頁冊數:	129 p.
附註:	Major Professor: Tania Phillips.
Contained By:	Dissertation Abstracts International66-04B.
標題:	Health Sciences, Immunology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3171120
ISBN:	9780542078927

An open-label, randomized, prospective study to evaluate the effectiveness and safety of continuous long-term versus intermittent etanercept in the treatment of psoriasis.
Al-Abdouli, Khuloud Asad.

An open-label, randomized, prospective study to evaluate the effectiveness and safety of continuous long-term versus intermittent etanercept in the treatment of psoriasis. - 129 p.

Major Professor: Tania Phillips.

Thesis (Sc.D.)--Boston University, 2005.

Aim. To evaluate the effectiveness and safety of continuous long-term versus intermittent etanercept in the treatment of psoriasis.

ISBN: 9780542078927Subjects--Topical Terms:

1017716
Health Sciences, Immunology.

An open-label, randomized, prospective study to evaluate the effectiveness and safety of continuous long-term versus intermittent etanercept in the treatment of psoriasis.
LDR:03522nam 2200325 a 45 001 970608
005 20110921
008 110921s2005 eng d
020 $a 9780542078927
035 $a (UMI)AAI3171120
035 $a AAI3171120
040 $a UMI $c UMI
100 1 $a Al-Abdouli, Khuloud Asad. $3 1294648
245 1 3 $a An open-label, randomized, prospective study to evaluate the effectiveness and safety of continuous long-term versus intermittent etanercept in the treatment of psoriasis.
300 $a 129 p.
500 $a Major Professor: Tania Phillips.
500 $a Source: Dissertation Abstracts International, Volume: 66-04, Section: B, page: 1966.
502 $a Thesis (Sc.D.)--Boston University, 2005.
520 $a Aim. To evaluate the effectiveness and safety of continuous long-term versus intermittent etanercept in the treatment of psoriasis.
520 $a Background. Psoriasis is recognized as the most prevalent T cell-mediated immune disease in which CD4+ and CD8 + memory effector T cells stimulate the hyperproliferation of keratinocytes. TNF is a pro-inflammatory cytokine known to play an important role in the pathogenesis of psoriasis. Etanercept acts as a competitive inhibitor of tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors.
520 $a Method. All patients (n = 9) received etanercept 50 mg twice weekly SC for the first 12 weeks. At week 12 patients were randomized equally (1:1) to one of two treatment groups, the continuous therapy and intermittent therapy. The continuous therapy group received etanercept 50 mg once weekly SC for weeks 13 through 24. The intermittent therapy group was assessed for response. Those who achieved a responder status (PGA score ≤ 2 and improved from baseline) at week 12 discontinued therapy. Upon relapse of PGA responder status at week 16 or 20, etanercept will resumed at a dose of 50 mg once weekly SC through week 24. Patients who had not achieved a responder status on PGA at week 12 continued etanercept without interruption, as in the continuous therapy group.
520 $a Results. In the first 12 weeks, all patients (n = 9) improved in all three parameters, BSA% (P = 0.048), PGA (p = 0.013), and Scalp score (p = 0.0083). These results demonstrated statistically significant improvement compared to baseline. In the second half of the study, (from week 12 to 24) there was statistically significant difference in BSA% in the continuous therapy group compared to the intermittent therapy group (p = 0.012). However there was no difference in PGA (p = 0.12) and Scalp score (p = 0.34).
520 $a Conclusion. Our study shows that continuous therapy appears to be more effective than intermittent therapy with improvement in BSA%. Relapse (defined as PGA > 2) only occurred in the intermittent group. Two patients relapsed at week 16 (40%), one relapsed at week 20 (20%), and two did not relapse by 24 weeks. Etanercept was safe and well tolerated in both groups. No serious events occurred during the study. Three patients (3/9) had the most common drug related adverse events, injection site reactions (33%). Four patients (4/9) did not have drug related adverse events. Other adverse events were considered unrelated to the study drug.
590 $a School code: 0017.
650 4 $a Health Sciences, Immunology. $3 1017716
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0419
690 $a 0982
710 2 0 $a Boston University. $3 1017454
773 0 $t Dissertation Abstracts International $g 66-04B.
790 $a 0017
790 1 0 $a Phillips, Tania, $e advisor
791 $a Sc.D.
792 $a 2005
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3171120